Compare BGSF & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSF | GRML |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0M | 51.5M |
| IPO Year | 2013 | 2022 |
| Metric | BGSF | GRML |
|---|---|---|
| Price | $5.53 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.6K | ★ 3.4M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 36.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,310,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.26 | $0.27 |
| 52 Week High | $8.20 | $0.55 |
| Indicator | BGSF | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 31.62 |
| Support Level | $5.49 | N/A |
| Resistance Level | $5.79 | $0.44 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 90.65 | 3.66 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.